نتایج جستجو برای: pharmacogenetic

تعداد نتایج: 2484  

2016
Franco De Crescenzo Stefano Vicari Luigi Mazzone Maria Pontillo Marco Armando

Evidence is growing that pharmacogenetic outcomes are related to drug resistance. We undertook genetic tests in order to study pharmacogenetic variables in two severely ill adolescent patients who were resistant to therapy. These two patients had different psychiatric conditions (patient A with attention deficit and hyperactivity disorder, patient B with bipolar disorder). They presented at bas...

2012
J. J. Brugts M. P. M. de Maat A. H. J. Danser E. Boersma M. L. Simoons

In patients with stable coronary artery disease (CAD) without overt heart failure, ACE inhibitors are among the most commonly used drugs as these agents have been proven effective in reducing the risk of cardiovascular events. Considerable individual variations in the blood pressure response to ACE inhibitors are observed and as such heterogeneity in clinical treatment effect would be likely as...

2018
Barbara Jenko Matija Tomšič Biljana Jekić Vera Milić Vita Dolžan Sonja Praprotnik

Objectives: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether this model can be generalized to other populations by validating it on a group of Serbian RA patient...

2012
Alberto M. Borobia Rubin Lubomirov Elena Ramírez Alicia Lorenzo Armando Campos Raul Muñoz-Romo Carmen Fernández-Capitán Jesús Frías Antonio J. Carcas

Appropriate dosing of coumarins is difficult to establish, due to significant inter-individual variability in the dose required to obtain stable anticoagulation. Several genetic and other clinical factors have been associated with the coumarins dose, and some pharmacogenetic-guided dosing algorithms for warfarin and acenocoumarol have been developed for mixed populations. We recruited 147 patie...

Journal: :Pharmacotherapy 2009
Kelan L H Thomas Vicki L Ellingrod

The selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely prescribed classes of drugs. They are relatively safe for the pharmacologic treatment of various psychiatric disorders; however, certain patients cannot tolerate some adverse drug reactions associated with this drug class. In addition, clinicians currently have no way to predict who will respond appropriately...

Journal: :Actas espanolas de psiquiatria 2010
A Gesteira F Barros A Martín V Pérez A Cortés M Baiget A Carracedo

Based on present knowledge, in this work we review the importance of the pharmacogenetic tests in the treatment with antipsychotic drugs. Many associations have been reported between different genetic markers and response to treatment as well as to the appearance of adverse reactions. However, up to now, no "prime" biomarker capable of unequivocally predicting the clinical benefits of a specifi...

Journal: :Clinical pharmacology and therapeutics 2008
B F Gage C Eby J A Johnson E Deych M J Rieder P M Ridker P E Milligan G Grice P Lenzini A E Rettie C L Aquilante L Grosso S Marsh T Langaee L E Farnett D Voora D L Veenstra R J Glynn A Barrett H L McLeod

Initiation of warfarin therapy using trial-and-error dosing is problematic. Our goal was to develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 participants, the independent predictors of therapeutic dose were: VKORC1 polymorphism -1639/3673 G>A (-28% per allele), body surface area (BSA) (+11% per 0.25 m(2)), CYP2C9(*)3 (-33% per allele), CYP2C9(*)2 (-19% per all...

2015
Amber L Beitelshees Deepak Voora Joshua P Lewis

In recent years, substantial effort has been made to better understand the influence of genetic factors on the efficacy and safety of numerous medications. These investigations suggest that the use of pharmacogenetic data to inform physician decision-making has great potential to enhance patient care by reducing on-treatment clinical events, adverse drug reactions, and health care-related costs...

Journal: :The Journal of molecular diagnostics : JMD 2010
Victoria M Pratt Barbara Zehnbauer Jean Amos Wilson Ruth Baak Nikolina Babic Maria Bettinotti Arlene Buller Ken Butz Matthew Campbell Chris Civalier Abdalla El-Badry Daniel H Farkas Elaine Lyon Saptarshi Mandal Jason McKinney Kasinathan Muralidharan LeAnne Noll Tara Sander Junaid Shabbeer Chingying Smith Milhan Telatar Lorraine Toji Anand Vairavan Carlos Vance Karen E Weck Alan H B Wu Kiang-Teck J Yeo Markus Zeller Lisa Kalman

Pharmacogenetic testing is becoming more common; however, very few quality control and other reference materials that cover alleles commonly included in such assays are currently available. To address these needs, the Centers for Disease Control and Prevention's Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and th...

Journal: :Clinical pharmacology and therapeutics 2008
J J Swen I Wilting A L de Goede L Grandia H Mulder D J Touw A de Boer J M H Conemans T C G Egberts O H Klungel R Koopmans J van der Weide B Wilffert H-J Guchelaar V H M Deneer

Despite initial enthusiasm, the use of pharmacogenetics has remained limited to investigation in only a few clinical fields such as oncology and psychiatry. The main reason is the paucity of scientific evidence to show that pharmacogenetic testing leads to improved clinical outcomes. Moreover, for most pharmacogenetic tests (such as tests for genetic variants of cytochrome P450 enzymes) a detai...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید